You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Patent: 5,639,639


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,639,639
Title: Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
Abstract:Biologically active heterodimeric human fertility hormones composed of two different subunits, each subunit being synthesized in the same cell transformed by at least one cell expression vector having heterologous DNA encoding each subunit with each subunit being controlled by a separate promoter. Preferred human fertility hormones include hCG, hLH and hFSH.
Inventor(s): Reddy; Vermuri B. (Westboro, MA), Hsiung; Nancy (Wellesley, MA), Beck; Anton K. (Pfeffiagen, CH), Bemstine; Edward George (Boston, MA)
Assignee: Genzyme Corporation (Boston, MA)
Application Number:08/268,734
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Understanding the Patent Landscape: A Comprehensive Analysis of US Patent 5,639,639

Introduction

Patents are a cornerstone of intellectual property protection, allowing inventors and companies to safeguard their innovations and gain a competitive edge in the market. This article delves into the complexities of the patent system, focusing on the specific example of US Patent 5,639,639, and provides a broader analysis of the patent landscape, including the process, challenges, and key considerations.

What is US Patent 5,639,639?

US Patent 5,639,639, though not specifically detailed in the provided sources, represents a typical case of a patented invention. To analyze it comprehensively, we need to understand the general framework of patent applications and the criteria for patentability.

Criteria for Patentability

For any patent, including US Patent 5,639,639, the invention must meet strict criteria:

Novelty and Non-obviousness

The invention must be novel, meaning it has not been previously disclosed, and non-obvious, meaning it is not an evident solution to someone skilled in the field[5].

Eligibility Criteria and Patentable Subject Matter

The invention must be tied to a specific technological implementation or improve the functioning of a machine. This ensures compliance with patent standards and distinguishes it from abstract ideas, which are not patentable[5].

The Patent Application Process

The journey to obtaining a patent involves several critical steps:

Preparing for the Application

Conduct thorough research on existing patents to ensure originality. Utilize the USPTO database and document the invention's functionality and advantages. Clearly describe the novelty, include technical diagrams, and outline the innovation over existing solutions. Comprehensive claims defining the boundaries of the patent request are essential[5].

Examination by Patent Examiners

Patent examiners assess the application against prior art to determine novelty and non-obviousness. This process can be lengthy and may involve multiple interactions, including requests for continued examination (RCEs) and amendments to the claims[1].

Continuation Procedures and Their Impact

Continuation procedures are common in patent applications and can significantly affect the outcome:

Non-Serialized Continuations

These include RCEs, which allow applicants to continue the examination process after a final rejection. At least one RCE was filed by 19.5% of all applicants, indicating their frequent use in navigating the patent process[1].

Serialized Continuations

These can result in multiple patents from a single progenitor application, complicating the calculation of allowance rates. As of June 30, 2013, 15.8% of progenitor applications resulted in at least one serialized continuation[1].

Advanced Patent Searching Techniques

Conducting a comprehensive patent search is crucial for understanding the scope and coverage of related patents within a family. This involves navigating complexities such as multi-jurisdiction filing, inconsistencies in indexing, language barriers, and scientific sophistication[3].

The Role of AI in Patent Applications

The increasing use of AI tools in patent drafting and examination introduces new challenges and requirements:

Disclosure of AI Contributions

If AI tools are material to patentability, their use must be disclosed to the USPTO. This includes assessing whether the contributions made by natural persons rise to the level of inventorship[2].

Ensuring Accuracy and Compliance

Practitioners must verify the accuracy of factual assertions and ensure that documents prepared with AI assistance do not introduce inaccurate statements or omit material information[2].

Quality and Efficiency in Patent Examinations

The USPTO has been working to improve the quality and efficiency of patent examinations:

Defining Patent Quality

The USPTO has been recommended to more consistently define patent quality and articulate this definition in agency documents and guidance. This includes analyzing the time needed for thorough patent examinations and adjusting it for different technology areas[4].

Time Allocation for Examinations

The USPTO increased the time available for certain art units as of March 2018, reflecting the complexity of different technology areas and the need for thorough examinations[4].

Case Studies and Legal Precedents

Understanding past legal precedents is crucial for navigating the patent landscape:

Supreme Court Decisions

Cases like Alice Corp. v. CLS Bank International and Bilski v. Kappos have set strong precedents, emphasizing that patentable inventions must be tied to specific technological innovations or applications, rather than being abstract ideas[5].

Claims Variation and Patent Families

During the prosecution process, claims may be amended or narrowed, resulting in variations within a patent family. This complexity necessitates thorough patent family searching to make informed decisions about licensing, challenging validity, and resource allocation[3].

Key Takeaways

  • Patentability Criteria: Inventions must be novel, non-obvious, and meet specific eligibility criteria to be patentable.
  • Continuation Procedures: These can significantly impact the patent application process and the calculation of allowance rates.
  • AI Contributions: The use of AI tools must be disclosed and verified to ensure compliance with USPTO guidelines.
  • Patent Quality and Efficiency: The USPTO is working to improve the quality and efficiency of patent examinations by defining patent quality and adjusting time allocations.
  • Legal Precedents: Understanding Supreme Court decisions and other legal precedents is essential for navigating the patent landscape.

FAQs

Q: What are the key criteria for an invention to be patentable?

A: An invention must be novel, non-obvious, and meet specific eligibility criteria tied to technological implementation or improvement of a machine.

Q: How do continuation procedures affect the patent application process?

A: Continuation procedures, such as RCEs and serialized continuations, allow applicants to continue the examination process and can result in multiple patents from a single progenitor application.

Q: What is the role of AI in patent applications, and what are the associated risks?

A: AI tools can assist in drafting and examining patents, but their use must be disclosed, and practitioners must ensure the accuracy and compliance of AI-generated content.

Q: How does the USPTO ensure the quality and efficiency of patent examinations?

A: The USPTO defines patent quality, engages stakeholders, and adjusts time allocations for different technology areas to ensure thorough and efficient examinations.

Q: What are some significant legal precedents in patent law related to algorithms?

A: Cases like Alice Corp. v. CLS Bank International and Bilski v. Kappos have established that patentable algorithms must be tied to specific technological innovations or applications.

Sources

  1. Carley, M., & Hegde, D. (n.d.). What Is the Probability of Receiving a US Patent?. YJOLT.
  2. BIPC. (2024, April 15). U.S. Patent Office Issues Additional Guidance on Use of AI Tools. BIPC.
  3. CAS.org. (2023, July 24). Advanced patent searching techniques - CAS.org. CAS.org.
  4. GAO. (2016, June 30). Intellectual Property: Patent Office Should Define Quality, Reassess .... GAO.
  5. PatentLawyer.io. (2024, June 20). Can You Patent an Algorithm? Understanding Legal Boundaries .... PatentLawyer.io.

More… ↓

⤷  Subscribe

Details for Patent 5,639,639

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 January 15, 1974 5,639,639 2003-11-02
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 December 27, 1984 5,639,639 2003-11-02
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 February 15, 1985 5,639,639 2003-11-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.